Get started
Author

Esther S. Trueblood

Observed names: E S Trueblood, E Trueblood, E. S. Trueblood, E. Trueblood, Esther S Trueblood, Esther Trueblood, Trueblood, Esther S.
ORCID: 0000-0002-0229-8491
Observed ORCID: 0000-0002-0229-8491
OpenAlex ID: A5021344389
Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation
2007 · Hal Blumberg, Huyen Dinh, et al. · The Journal of Experimental Medicine · 355
PDF
Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues: Potential Implications as a Cancer Therapeutic Target
2011 · Lara P. Stepan, Esther S. Trueblood, et al. · Journal of Histochemistry & Cytochemistry · 288
IL-1RL2 and Its Ligands Contribute to the Cytokine Network in Psoriasis
2010 · Hal Blumberg, Huyen Dinh, et al. · The Journal of Immunology · 163
Mechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis
2008 · Afsaneh Mozaffarian, Avery W. Brewer, et al. · The Journal of Immunology · 153
PDF
Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways
2019 · Kent Miner, Katja Labitzke, et al. · Frontiers in Pharmacology · 124
PDF
AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
2015 · Kevin J. Hamblett, Carl J. Kozlosky, et al. · Molecular Cancer Therapeutics · 106
Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
2023 · Ryan A. Heiser, Anthony T. Cao, et al. · Molecular Cancer Therapeutics · 82
PDF
Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity
2006 · Gregory N. Dietsch, Chris R. Dipalma, et al. · Toxicologic Pathology · 59
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models
2023 · Elizabeth Gray, Michelle Ulrich, et al. · Journal for ImmunoTherapy of Cancer · 51
PDF
B-Lymphocyte Proliferation during Bovine Leukemia VirusInduced Persistent Lymphocytosis Is Enhanced by T-Lymphocyte-Derived Interleukin-2
1998 · Esther S. Trueblood, Wendy C. Brown, et al. · Journal of Virology · 48
Retinal Toxicity Induced by a Novel β-secretase Inhibitor in the Sprague-Dawley Rat
2014 · Mark R. Fielden, Jonathan Werner, et al. · Toxicologic Pathology · 42
SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
2023 · Robert P. Lyon, Mechthild Jonas, et al. · Molecular Cancer Therapeutics · 38
PDF
Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
2012 · E Girard, C Strathdee, et al. · British Journal of Cancer · 33
PDF
Canine Fatalities Associated with the use of a Modified Live Vaccine Administered during Late Stages of Pregnancy
1994 · J. F. Evermann, A. J. McKeiman, et al. · Journal of Veterinary Diagnostic Investigation · 29
Antagonists of CD117 (cKit) signaling inhibit mast cell accumulation in healing skin wounds
2008 · Stephen J. Zoog, Andrea Itano, et al. · Cytometry Part A · 15
PDF
253
2013 · Yu Sun, Afsaneh Mozaffarian, et al. · Cytokine · 10
Detection of Anaplasma marginale rickettsemia prior to onset of clinical signs by using an antigen capture enzyme-linked immunosorbent assay
1991 · E S Trueblood, T C McGuire, et al. · Journal of Clinical Microbiology · 10
617 Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death
2020 · Elizabeth Gray, Kelly Hensley, et al. · Journal for ImmunoTherapy of Cancer · 9
854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models
2021 · Elizabeth Gray, Angela Epp, et al. · Journal for ImmunoTherapy of Cancer · 5
PDF
Abstract 1766: SGN-ALPV a novel, investigational vedotin ADC demonstrates highly effective targeting of oncofetal phosphatases ALPP and ALPPL2 in preclinical models
2022 · Sarah Anderson, Nanna Hansen, et al. · Cancer Research · 4
347 POSTER The RANK ligand inhibitor OPG-Fc reduces bone lesions and skeletal tumor burden in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models
2006 · R. Miller, J. Jones, et al. · European Journal of Cancer Supplements · 4
Abstract 1140: Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer
2022 · Christopher Carosino, Devra Olson, et al. · Cancer Research · 3
Abstract 2688: SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors
2019 · Sharsti L. Sandall, Marsha Mason, et al. · Cancer Research · 3
Abstract 2906: SGN-B6A: A new MMAE ADC targeting integrin beta-6 in multiple carcinoma indications
2020 · Robert P. Lyon, Michael W. Schmitt, et al. · Cancer Research · 2
Table S1 from Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity
2024 · Ryan A. Heiser, Anthony T. Cao, et al. · 1
Works count: 90
Citation count: 1,661
H-index: 15
I10-index: 18
Year
Topic
Type